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Abstract
Background: Anticardiolipin	(aCL)	and	anti-β2	glycoprotein	I	(aβ2GPI)	immunoglobulin	
(Ig)	G/IgM	antibodies	are	2	of	the	3	laboratory	criteria	for	classification	of	antiphos-
pholipid	syndrome	(APS).	The	threshold	for	clinically	relevant	levels	of	antiphospho-
lipid	antibodies	(aPL)	for	the	diagnosis	of	APS	remains	a	matter	of	debate.	The	aim	of	
this	study	was	to	evaluate	the	variation	in	cutoffs	as	determined	in	different	clinical	
laboratories	based	on	the	results	of	a	questionnaire	as	well	as	to	determine	the	optimal	
method	for	cutoff	establishment	based	on	a	clinical	approach.
Methods: The	study	included	samples	from	114	patients	with	thrombotic	APS,	138	
patients	with	non-APS	thrombosis,	138	patients	with	autoimmune	disease,	and	183	
healthy	controls.	aCL	and	aβ2GPI	IgG/IgM	antibodies	were	measured	at	1	laboratory	
using	4	 commercial	 assays.	Assay-specific	 cutoff	 values	 for	 aPL	were	obtained	by	
determining	95th	and	99th	percentiles	of	120	compared	to	200	normal	controls	by	
different	statistical	methods.
Results: Normal	reference	value	data	showed	a	nonparametric	distribution.	Higher	
cutoff	 values	 were	 found	 when	 calculated	 as	 99th	 rather	 than	 95th	 percentiles.	
These	values	also	showed	a	stronger	association	with	thrombosis.	The	use	of	99th	
percentile	cutoffs	reduced	the	chance	of	false	positivity	but	at	the	same	time	reduced	
sensitivity.	The	decrease	in	sensitivity	was	higher	than	the	gain	in	specificity	when	
99th	percentiles	were	calculated	by	methods	wherein	no	outliers	were	eliminated.
Conclusions: We	present	 cutoff	 values	 for	 aPL	determined	by	different	 statistical	
methods.	The	99th	percentile	cutoff	value	seemed	more	specific.	However,	our	find-
ings	indicate	the	need	for	standardized	statistical	criteria	to	calculate	99th	percentile	
cutoff	reference	values.
K E Y W O R D S
antiphospholipid	antibodies,	clinical	laboratory	testing,	immunoassay,	reference	values,	
thrombosis
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1  | INTRODUCTION
According	 to	 the	 updated	 Sapporo	 criteria,	 the	 diagnosis	 of	 an-
tiphospholipid	syndrome	 (APS)	 implies	vascular	 thrombosis	and/or	
pregnancy	morbidity	and	at	 least	1	of	the	3	antiphospholipid	anti-
bodies	 (aPLs)	 (ie,	 lupus	 anticoagulant	 [LAC],	 anticardiolipin	 [aCL]
immunoglobulin	 (Ig)	 G/IgM	 antibodies	 and	 anti-β2	 glycoprotein	 I	
[aβ2GPI]	 IgG/IgM	 antibodies).1	 The	 “classical”	 clinical	 characteris-
tics	 of	APS	 include	 vascular	 thrombosis	 and	pregnancy	morbidity.	
However,	APS	may	be	associated	with	a	wide	variety	of	other	clinical	
symptoms,	including	thrombocytopenia,	heart	valve	disease,	livedo	
reticularis,	nephropathy,	and	neurological	manifestations,	which	are	
considered	noncriteria	manifestations	of	APS.1,2	In	view	of	the	lack	
of	 specificity	of	 the	clinical	manifestations	 (in	particular	when	 the	
classical	clinical	characteristics	are	absent),	laboratory	tests	for	aPL	
are	crucial	to	diagnose	APS.	The	persistent	positivity	of	laboratory	
tests	is	important	because	the	transient	presence	of	epiphenomenal	
aPL	may	give	rise	to	misclassification.	Thereby,	classification	criteria	
emphasize	the	importance	of	repeating	positive	tests	at	an	interval	
of	>12	weeks.1
Traditionally,	aCL	and	aβ2GPI	antibodies	are	detected	by	enzyme-
linked	immunosorbent	assay	(ELISA),	although	new,	fully	automated	
technologies	 such	 as	 chemiluminescent	 and	 fluorescence	 enzyme	
immunoassays	 have	 been	 introduced.	 The	 new	 assays	 show	 good	
analytical	performance.3,4	For	all	assays,	the	cutoff	value	should	be	
carefully	chosen	because	the	sensitivity	and	specificity	of	diagnos-
tic	laboratory	testing	for	aPL	strongly	depend	on	the	cutoff	value.5 
In	analogy	with	LAC,	the	Scientific	and	Standardization	Committee	
on	 Lupus	 Anticoagulant/Antiphospholipid	 Antibodies	 (SSC-aPL)	 of	
the	 International	 Society	 of	 Thrombosis	 and	 Haemostasis	 (ISTH)	
recommends	the	use	of	the	99th	percentile	of	a	reference	popula-
tion	as	the	cutoff	to	maximize	specificity.6,7	Therefore,	a	minimum	
of	120	reference	subjects	should	be	used,	taking	into	consideration	
the	age	and	type	of	population	most	representative	for	each	labo-
ratory.6	Unfortunately,	these	in-house	calculated	cutoff	values	may	
be	significantly	different	from	those	recommended	by	the	manufac-
turers.8‒10	In	fact,	the	value	may	depend	on	the	performance	char-
acteristics,	the	statistical	method	and	the	reference	population	used	
to	establish	cutoff	values.	Reaching	a	consensus	on	the	method	for	
cutoff	establishment	is	important	from	the	viewpoint	of	harmoniza-
tion	of	aPL	measurement.
To	 study	 cutoff	 establishment	 in	 clinical	 laboratories,	 we	 pre-
pared	 a	 questionnaire	 sent	 to	 SSC-aPL	members	 and	 participants	
of	 the	 Lupus	 Anticoagulant/Antiphospholipid	 Antibodies	 Program	
of	the	ECAT	(External	Quality	Control	for	Assays	and	Tests)	(ECAT	
Foundation,	Voorschoten,	The	Netherlands).	 Subsequently,	we	 set	
up	 a	 study	 to	 further	 investigate	 the	extent	of	 differences	 in	 cut-
off	values	determined	by	different	methods	of	calculation.	A	patient	
population	was	used	to	assess	the	impact	of	different	cutoff	values	
on	 the	analytical	 and	clinical	 performance	of	4	 commercial	 assays	
detecting	aPL.
2  | MATERIALS AND METHODS
2.1 | Questionnaire on cutoff values for aPL with 
solid‐phase assays
A	questionnaire	(see	the	Supplementary	Data)	was	sent	by	email	to	
318	SSC-aPL	members	and	575	participants	of	the	“Lupus	Program”	
external	quality	exercises	of	 the	ECAT	Foundation.	SSC-aPL	mem-
bers	are	workers	in	the	field	of	aPL	who	expressed	their	interest	in	
the	SSC-aPL	by	signing	up	on	the	ISTH	website.
2.2 | Selection of normal controls
A	total	of	120	normal	controls	(71	females	and	49	males;	mean	age,	
56	years;	range,	44-65	years)	were	recruited	from	healthy	local	vol-
unteers	at	Ghent	University	Hospital	(Ghent,	Belgium).	In	collabora-
tion	with	Jagiellonian	University	Medical	College	(Krakow,	Poland),	
the	normal	population	was	expanded	with	another	80	healthy	volun-
teers,	giving	rise	to	a	sample	size	of	200	(129	females	and	71	males;	
mean	age,	53	years;	range,	20-71	years).	All	healthy	volunteers	were	
selected	for	blood	sampling	after	declaring	good	health	by	a	ques-
tionnaire.	They	were	free	from	overt	cardiovascular	disease,	conven-
tional	risk	factors,	and	medication.
2.3 | Selection of patient groups
Patients	with	APS,	patients	with	non-APS	disease,	and	healthy	con-
trols	 were	 enrolled	 at	 Ghent	 University	 Hospital	 and	 Jagiellonian	
University	Medical	College.	The	patients	were	selected	by	the	en-
rollment	center	out	of	a	population	referred	for	autoimmune	disease,	
hypercoagulability,	or	prolonged	clotting	time	with	a	request	for	aPL	
measurement.	They	were	assigned	to	the	following	categories	based	
on	both	clinical	data	and	results	of	local	laboratory	investigations:
1.	 Group	 A	 consisted	 of	 patients	 with	 thrombotic	 APS	 according	
to	 the	 Sydney	 revised	 Sapporo	 guidelines.1	 Of	 these	 patients,	
Essentials
•	 Cutoff	values	for	antiphospholipid	antibodies	remain	a	matter	of	debate.
•	 Cutoff	values	were	derived	from	testing	200	normal	controls	with	4	commercial	assays.
•	 Large	cutoff	variations	were	observed	by	different	methods	of	calculation.
•	 Standardized	statistical	criteria	to	calculate	99th	percentile	cutoff	reference	values	are	needed.
     |  517VANOVERSCHELDE Et AL.
TA
B
LE
 1
 
A
ss
ay
	c
ha
ra
ct
er
is
tic
s
 
H
em
os
IL
 A
cu
St
ar
Bi
oP
le
x
El
iA
Q
U
A
N
TA
 L
ite
A
ss
ay
H
em
os
IL
	A
cu
St
ar
	
A
nt
i-β
2	
gl
yc
op
ro
-
te
in
	I	
Ig
M
,	I
gG
H
em
os
IL
	A
cu
St
ar
	
A
nt
i-C
ar
di
ol
ip
in
	
Ig
M
,	I
gG
A
PL
S	
Ig
M
	k
it
A
PL
S	
Ig
G
	k
it
El
iA
	β
2-
G
ly
co
pr
ot
ei
n	
I	I
gM
,	I
gG
El
iA
	C
ar
di
ol
ip
in
	
Ig
M
,	I
gG
Q
U
A
N
TA
	L
ite
	β
2G
PI
	
Ig
M
,	I
gG
Q
U
A
N
TA
	L
ite
	
AC
A
	Ig
M
,	I
gG
	II
I
Te
ch
no
lo
gy
A
ut
om
at
ed
	2
-s
te
p	
ch
em
ilu
m
in
es
ce
nt
	
im
m
un
oa
ss
ay
A
ut
om
at
ed
	2
-s
te
p	
ch
em
ilu
m
in
es
ce
nt
	
im
m
un
oa
ss
ay
A
ut
om
at
ed
	m
ul
tip
le
x	
flo
w
	im
m
un
oa
ss
ay
A
ut
om
at
ed
	
m
ul
tip
le
x	
flo
w
	
im
m
un
oa
ss
ay
Fl
uo
re
sc
en
ce
	e
n-
zy
m
e	
im
m
un
oa
ss
ay
Fl
uo
re
sc
en
ce
	
en
zy
m
e	
im
m
un
oa
ss
ay
En
zy
m
e-
lin
ke
d	
im
m
u-
no
so
rb
en
t	a
ss
ay
En
zy
m
e-
lin
ke
d	
im
m
un
os
or
be
nt
	
as
sa
y
C
oa
tin
g	
w
el
l/
pa
rt
ic
le
H
um
an
 β
2G
PI
Bo
vi
ne
	c
ar
di
ol
ip
in
	
w
ith
 h
um
an
 β
2G
PI
1:
 H
um
an
 β
2G
PI
2:
	S
yn
th
et
ic
	c
ar
di
-
ol
ip
in
	w
ith
	h
um
an
	
β2
G
PI
1:
 H
um
an
 β
2G
PI
2:
	S
yn
th
et
ic
	c
ar
di
-
ol
ip
in
	w
ith
	h
um
an
	
β2
G
PI
H
um
an
 β
2G
PI
Bo
vi
ne
	c
ar
-
di
ol
ip
in
	a
nd
	
bo
vi
ne
 β
2G
PI
Pu
rif
ie
d	
β2
G
PI
Pu
rif
ie
d	
ca
rd
i-
ol
ip
in
	a
nd
	b
ov
in
e	
β2
G
PI
C
on
ju
ga
te
Is
ol
um
in
ol
-la
be
le
d	
an
ti-
hu
m
an
	Ig
M
/
Ig
G
	a
nt
ib
od
y
Is
ol
um
in
ol
-la
be
le
d	
an
ti-
hu
m
an
	Ig
M
/
Ig
G
	a
nt
ib
od
y
Ph
yc
oe
ry
th
rin
	
co
nj
ug
at
ed
	m
ur
in
e	
m
on
oc
lo
na
l	a
nt
i-
hu
m
an
	Ig
M
Ph
yc
oe
ry
th
rin
	
co
nj
ug
at
ed
	a
nt
i-
hu
m
an
	Ig
G
β-
ga
la
ct
os
id
as
e	
m
ou
se
	m
on
oc
lo
na
l	
an
ti-
	Ig
M
,	I
gG
β-
ga
la
ct
os
id
as
e	
m
ou
se
	m
on
o-
cl
on
al
	a
nt
i-I
gG
Pe
ro
xi
da
se
-la
be
le
d	
an
ti-
hu
m
an
	Ig
M
,	I
gG
Pe
ro
xi
da
se
-la
-
be
le
d	
an
ti-
hu
m
an
	Ig
M
,	I
gG
Si
gn
al
	 
de
te
ct
io
n
Ch
em
ilu
m
in
es
ce
nc
e
C
he
m
ilu
m
in
es
ce
nc
e
Fl
uo
re
sc
en
ce
Fl
uo
re
sc
en
ce
Fl
uo
re
sc
en
ce
Fl
uo
re
sc
en
ce
C
hr
om
og
en
ic
C
hr
om
og
en
ic
C
al
ib
ra
tio
n
In
te
rn
al
	s
ta
nd
ar
d	
tr
ac
ea
bl
e	
to
w
ar
ds
	
Ko
ik
e'
s	
m
on
o-
cl
on
al
	a
nt
ib
od
ie
s	
(H
C
A
L	
fo
r	I
gG
	a
nd
	
EY
2C
9	
fo
r	I
gM
)
In
te
rn
al
	s
ta
nd
ar
d	
tr
ac
ea
bl
e	
to
w
ar
ds
	
Ko
ik
e'
s	
m
on
o-
cl
on
al
	a
nt
ib
od
ie
s	
(H
C
A
L	
fo
r	I
gG
	a
nd
	
EY
2C
9	
fo
r	I
gM
)
In
te
rn
al
	s
ta
nd
ar
d	
co
nt
ai
ni
ng
	h
um
an
	
an
tib
od
ie
s	
in
	s
er
um
	
m
at
rix
In
te
rn
al
	s
ta
nd
ar
d	
co
nt
ai
ni
ng
	h
um
an
	
an
tib
od
ie
s	
in
	
se
ru
m
	m
at
rix
In
te
rn
al
	s
ta
nd
ar
d	
co
nt
ai
ni
ng
	h
um
an
	
Ig
G
	o
r	I
gM
	in
	P
BS
,	
tr
ac
ea
bl
e 
to
 th
e 
W
H
O
	In
te
rn
at
io
na
l	
Re
fe
re
nc
e	
Pr
ep
ar
at
io
n	
67
/8
6
In
te
rn
al
	s
ta
nd
ar
d	
co
nt
ai
ni
ng
	
hu
m
an
	Ig
G
	o
r	
Ig
M
	in
	P
BS
,	
tr
ac
ea
bl
e 
to
 
th
e	
W
H
O
	
In
te
rn
at
io
na
l 
Re
fe
re
nc
e	
Pr
ep
ar
at
io
n	
67
/8
6
In
te
rn
al
	s
ta
nd
ar
d	
co
nt
ai
ni
ng
	h
um
an
	
se
ru
m
	a
nt
ib
od
ie
s	
to
	
β2
G
PI
	re
fe
re
nc
ed
	to
	
th
e	
re
fe
re
nc
e	
ca
li-
br
at
or
s	
fo
r	I
gG
/I
gM
	
β2
G
PI
	a
va
ila
bl
e	
fr
om
	
th
e	
Rh
eu
m
at
ol
og
y	
La
bo
ra
to
ry
,	S
et
on
	
H
al
l	U
ni
ve
rs
ity
,	S
t.	
Jo
se
ph
's	
H
os
pi
ta
l	
an
d	
M
ed
ic
al
	C
en
te
r
In
te
rn
al
	s
ta
nd
ar
d	
co
nt
ai
ni
ng
	
hu
m
an
	s
er
um
	
an
tib
od
ie
s	
to
	
ca
rd
io
lip
in
M
an
uf
ac
tu
re
r's
	
cu
to
ff
20
	U
/m
L
20
	U
/m
L
20
	M
PL
-U
/m
L	
(a
C
L)
20
	U
/m
L	
(a
β2
G
PI
)
20
	G
PL
-U
/m
L	
(a
C
L)
20
		U
/m
L	
(a
β2
G
PI
)
10
	U
/m
L
10
	M
PL
-U
/m
L,
	
G
PL
-U
/m
L
20
	S
M
U
,	S
G
U
20
	M
PL
,	G
PL
C
al
cu
la
tio
n
25
0-
26
2	
bl
oo
d	
ba
nk
	d
on
or
s,
	9
9t
h	
pe
rc
en
til
e
25
0-
25
2	
bl
oo
d	
ba
nk
	d
on
or
s,
	9
9t
h	
pe
rc
en
til
e
30
0	
bl
oo
d	
ba
nk
	
do
no
rs
,	a
	re
co
m
-
m
en
de
d 
va
lu
e
30
0	
bl
oo
d	
ba
nk
	
do
no
rs
,	a
	re
co
m
-
m
en
de
d 
va
lu
e
40
0	
he
al
th
y	
su
b-
je
ct
s,
	a
	re
co
m
-
m
en
de
d 
va
lu
e
40
0 
he
al
th
y 
su
bj
ec
ts
,	a
	
re
co
m
m
en
de
d 
va
lu
e
11
-3
13
	n
or
m
al
	
do
no
rs
,	a
	re
co
m
-
m
en
de
d 
va
lu
e
48
8-
48
9	
no
rm
al
	
do
no
rs
,	a
	re
co
m
-
m
en
de
d 
va
lu
e
aβ
2G
PI
,	a
nt
i-β
2	
gl
yc
op
ro
te
in
	I	
an
tib
od
ie
s;
	a
C
L,
	a
nt
ic
ar
di
ol
ip
in
	a
nt
ib
od
ie
s;
	β
2G
PI
,	β
2	
gl
yc
op
ro
te
in
	I;
	G
PL
,	I
gG
	p
ho
sp
ho
lip
id
	u
ni
ts
;	M
PL
,	 
Ig
M
	p
ho
sp
ho
lip
id
	u
ni
ts
;	P
BS
,	p
ho
sp
ha
te
-b
uf
fe
re
d	
sa
lin
e;
	S
G
U
,	s
ta
nd
ar
d	
Ig
G
	u
ni
ts
;	S
M
U
,	s
ta
nd
ar
d	
Ig
M
	u
ni
ts
.
518  |     VANOVERSCHELDE Et AL.
24%	 had	 arterial	 thrombosis,	 67%	 had	 venous	 thrombosis,	 and	
10%	 had	 thrombosis	 in	 both	 vascular	 beds.	 Numbers	 in	 each	
center	 were	 as	 follows:	 Ghent,	 n	 =	 64;	 Krakow,	 n	 =	 50.
2.	 Group	B	consisted	of	patients	who	had	a	history	of	 thrombosis	
and	were	negative	for	laboratory	criteria	of	APS	(“diseased	con-
trols”).	Numbers	in	each	center	were	as	follows:	Ghent,	n	=	138;	
Krakow,	n	=	0.
3.	 Group	C	consisted	of	patients	with	an	autoimmune	disease	with-
out	 thromboembolic	 or	 pregnancy	 complications.	 Numbers	 in	
each	center	were	as	follows:	Ghent,	n	=	97;	Krakow,	n	=	41.
4.	 Group	D	 included	 patients	 fulfilling	 neither	 the	 clinical	 nor	 the	
laboratory	criteria	for	APS	and	tested	for	aPL	due	to	an	acciden-
tally	found	prolonged	activated	partial	thromboplastin	time	or	the	
appearance	of	clinical	symptoms	not	included	in	the	APS	classifi-
cation	criteria,	such	as	chorea,	migraine,	infertility,	etc.	(“healthy	
controls”).	 Numbers	 in	 each	 center	 were	 as	 follows:	 Ghent,	
n	=	183;	Krakow,	n	=	0.
The	study	was	approved	by	the	ethics	committees	of	both	centers	in-
cluded	in	the	study.
2.4 | Assays
Citrated	plasmas	from	all	patients	and	controls	were	retested	for	aCL	
and aβ2GPI	IgG/IgM	antibodies	at	1	site	(Ghent	University	Hospital)	
using	4	commercial	assays:
1.	 The	 HemosIL	 AcuStar	 antiphospholipid	 assay	 (Werfen/
Instrumentation	 Laboratory,	 Bedford,	MA)	 is	 a	 fully	 automated	
2-step	immunoassay	using	chemiluminescent	technology	for	de-
tecting	aCL	and	aβ2GPI	IgG/IgM	antibodies	on	the	ACL	AcuStar.
2.	 The	BioPlex	2200	APLS	IgG	and	IgM	kits	(Bio-Rad	Laboratories,	
Hercules,	CA)	use	multiplex	bead	technology	for	the	detection	of	
IgG/IgM	antibodies	to	cardiolipin	and	β2GPI.
3.	 The	EliA	Cardiolipin	IgG,	IgM	and	EliA	β2-Glycoprotein	I	IgG,	IgM	
(Thermo	 Fisher	 Scientific/Phadia,	 Uppsala,	 Sweden)	 use	 fluo-
rescence	enzyme	immunoassay	technology	to	measure	aCL	and	
aβ2GPI	IgG/IgM	antibodies	on	the	Phadia	250	instrument.
4.	 The	QUANTA	Lite	ACA	IgG,	IgM	III	and	QUANTA	Lite	β2GPI	IgG,	
IgM	(Werfen/Inova	Diagnostics,	San	Diego,	CA)	ELISAs	were	per-
formed	manually	according	to	the	manufacturer's	instructions.
Table	1	gives	information	on	the	assays,	including	the	test	princi-
ple,	mode	of	detection,	and	manufacturer's	cutoff.
2.5 | Statistical analysis
All	 results	 from	 normal	 controls	 were	 tested	 to	 assess	 deviation	
from	the	normal	distribution	by	means	of	the	Kolmogorov-Smirnov	
test.	Cutoff	values	for	aPL	were	obtained	by	determining	95th	per-
centiles	(with	90%	confidence	intervals	[CIs])	and	99th	percentiles	
(with	90%	CIs)	by	using	2	methods.	One	method	(method	A),	cited	
by	the	Clinical	Laboratory	Standards	Institute	(CLSI),11	calculates	an	TA
B
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index	p	 (n	+	1)	with	p	 representing	 the	percentile	and	n	 the	 sam-
ple	size.	Method	B	calculates	an	 index	pn	+	0.5.	Secondary	analy-
ses	were	performed	when	outliers	were	first	eliminated.	To	identify	
outliers	Reed's	modification	of	the	Dixon	test12	and	Tietjen-Moore	
(TM)	 test13	 were	 used.	 To	 determine	 the	 number	 of	 outliers	 for	
the	TM	test,	we	chose	the	position	of	the	largest	gap.	Tukey's	box	
method	was	not	applied	because	it	requires	Box-Cox	transformation	
of	the	data	to	obtain	a	Gaussian	distribution	that	was	not	possible	
for	our	data	sets.
Cohen's	kappa	agreement	 test	was	carried	out	 to	assess	analytical	
agreement	 among	 aPL	 assays.	 To	evaluate	 the	 ability	 of	 the	 assays	 to	
predict	thrombotic	complications,	odds	ratios	(with	95%	CIs),	sensitivities	
(with	95%	CIs),	specificities	(with	95%	CIs),	and	Youden	indexes	(sensitivi-
ty+specificity−100%)	were	calculated,	considering	groups	A	and	B	as	clin-
ically	positive	and	all	other	groups	as	clinically	negative.	Clinically	affected	
(groups	A	and	B)	and	non–clinically	affected	patients	(groups	C	and	D)	
were	set	as	outcome	variable	rather	than	APS/non-APS	 in	order	to	be	
independent	of	aPL	presence	previously	detected	to	minimize	selection	
bias.	P	 values	 associated	with	 odds	 ratios	were	 calculated	 by	 Fisher's	
exact	test.	A	P	<	0.05	was	considered	to	be	statistically	significant.
All	 statistical	 analyses	were	performed	using	Analyse-it	 4.81.1	
for	Microsoft	Excel	(Analyse-it	Software,	Leeds,	UK),	MedCalc	17.5.5	
(MedCalc	 Software,	 Ostend,	 Belgium),	 and	 DATAPLOT	 software	
package	 6/2013	 (National	 Institute	 of	 Standards	 and	 Technology,	
Gaithersburg,	MD).
3  | RESULTS
3.1 | Questionnaire on cutoff values for aPL with 
solid‐phase assays
We	received	139	answers	from	all	over	the	world,	yielding	a	response	
rate	of	15.5%,	including	72.7%	hospital	laboratories.	A	total	of	61.4%	
of	 the	 responses	 originated	 from	 Europe,	 17.0%	 from	 the	 United	
States,	11.4%	from	Asia,	7.9%	from	South	America,	and	2.3%	from	
Australia.	Over	85%	of	the	participating	laboratories	performed	all	
F I G U R E  1  Results	of	the	questionnaire.	(A)	Which	statistical	method	do	you	use?	(B)	Which	method	do	you	use	to	identify	outliers?	IQR,	
interquartile	range;	SD,	standard	deviation
Parametric method without data
transformation, mean + 2 SD
(A)
(B)
Parametric method without data
transformation, mean + 3 SD
Parametric method after data
transformation to achieve
normality, mean + 2 SD
Nonparametric method: right-
sided percentile estimation after
data transformation to achieve
normality
I don’t check for outliers
Reed (modified Dixon)
Tukey (larger than upper
quartile plus 1.5 times IQR)
Tukey (larger than upper
quartile plus 2.2 times IQR)
Tukey (larger than upper
quartile plus 3 times IQR)
Visually
Nonparametric method: right-
sided percentile estimation 
without data transformation
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4	parameters	(aCL	IgG/IgM,	aβ2GPI	IgG/IgM)	with	various	methods.	
Tests	were	mainly	performed	in	coagulation	departments	(40.9%)	or	
clinical	chemistry/immunology	departments	(51.5%).
Furthermore,	41.1%	of	the	laboratories	calculated	in-house	cut-
off	values.	Most	of	the	laboratories	that	did	not	calculate	in-house	
cutoff	 values	 (58.9%)	used	 the	manufacturer's	 cutoff	 (75.7%).	The	
cost	and	availability	of	normal	donors	were	mentioned	as	the	main	
drawbacks	hampering	the	 in-house	calculation.	Only	38.2%	of	 the	
laboratories	checked	the	manufacturer's	cutoff	according	to	the	CLSI	
guideline	before	transference6,11;	44.1%,	30.3%,	and	44.1%	verified	
the	number	of	donors,	the	demographic	specifications,	and	the	sta-
tistical	 method	 used,	 respectively.	 The	minority	 (25%	 and	 38.7%)	
of	the	laboratories	rejected	the	manufacturer's	cutoff	if	fewer	than	
120	donors	were	used	or	the	statistical	method	did	not	conform	to	
the	recommendations.6	Furthermore,	53.7%	of	the	laboratories	that	
calculated	in-house	cutoff	values	used	120	or	more	normal	donors;	
in	81%	of	these	laboratories,	these	normal	donors	originated	from	a	
local	population	(laboratory	personnel)	or	blood	bank	donors.
The	question	“Which	statistical	method	do	you	use?”	revealed	a	para-
metric	method	in	41.6%	of	the	laboratories:	without	data	transformation	
(mean	+	2SD)	 in	19.4%,	without	data	transformation	 (mean	+	3SD)	 in	
13.9%,	and	after	data	transformation	to	achieve	normality	(mean	+	2SD)	
in	8.3%.	 In	 contrast,	58.4%	of	 the	 laboratories	used	a	nonparametric	
method:	right-sided	percentile	estimation	without	data	transformation	
in	41.7%	and	right-sided	percentile	estimation	after	data	transformation	
to	achieve	normality	in	16.7%	(Figure	1A).	Of	those	laboratories	apply-
ing	a	nonparametric	method,	82.4%	used	the	99th	percentile	(p	[n	+	1]	
[47.2%]	or	pn	+	0.5	[35.2%]),	and	17.6%	used	the	95th	percentile.
The	 question	 “Which	 method	 do	 you	 use	 to	 identify	 outliers?”	
showed	that	61.5%	of	the	laboratories	checked	for	outliers	by	different	
methods	as	illustrated	in	Figure	1B,	of	which	68.4%	effectually	excluded	
outliers;	31.6%	followed	the	recommendations	to	check	the	calculated	
cutoff	value	by	a	clinical	approach	in	the	local	patient	population	by	cal-
culating	sensitivity	and	specificity	regarding	the	association	with	throm-
botic/pregnancy	complications,6	and	72.7%	adapted	their	cutoff	values	
accordingly,	based	on	the	criterion	of	sensitivity	>95%	(37.5%),	specific-
ity	>95%	(37.5%)	or	choosing	the	highest	odds	ratio	(25%).
3.2 | Calculation of cutoff values on 
a normal population
The	results	for	aCL	and	aβ2GPI	IgG/IgM	antibodies	from	normal	con-
trols	showed	a	nonparametric	(positively	right	skewed)	distribution.	
Not	all	data	sets	could	be	normalized	due	to	the	clustering	of	identical	
low	values	at	the	bottom	of	the	distribution.	Hence,	it	was	decided	to	
calculate	cutoff	values	by	means	of	nonparametric	procedures.
The	derived	cutoff	values	for	aPL	are	presented	in	Tables	S1	and	
S2.	As	expected,	higher	cutoff	values	were	found	when	calculated	
as	99th	rather	than	95th	percentiles.	Notably,	the	statistical	method	
had	considerable	impact	on	the	estimated	cutoffs.	When	all	differ-
ent	methods	for	percentile	calculation	were	combined	with	all	dif-
ferent	outlier	elimination	methods	and	 the	99th	 (95th)	percentiles	
obtained	were	compared,	>11-	(>2-)	and	>8-	(>1-)	fold	difference	was	
obtained	using	data	from	120	and	200	normal	controls,	respectively.
The	99th	percentiles	of	120	normal	controls	by	method	A	were	
31.1	U/mL	for	aβ2GPI	IgM,	209.2	U/mL	for	aCL	IgM,	136.2	U/mL	for	
aβ2GPI	IgG,	and	42.5	U/mL	for	aCL	IgG	using	HemosIL	AcuStar.	For	
BioPlex,	these	values	were	found	to	be	65.4	U/mL,	59.8	MPL-U/mL,	
123.6	U/mL	and	132	GPL-U/mL,	respectively;	for	EliA,	21.3	U/mL,	
22.0	MPL-U/mL,	36.1	U/mL,	and	48.1	GPL-U/mL,	respectively;	and	
for	QUANTA	Lite,	24.6	SMU,	25.9	MPL,	16.4	SGU,	and	60.0	GPL,	
respectively.	The	99th	percentiles	with	the	use	of	method	A	were	
up	 to	2-fold	higher	 than	 those	of	method	B.	Moreover,	method	A	
produced	the	most	heavily	biased	estimates	compared	to	the	manu-
facturers’	cutoffs,	especially	for	the	lower	sample	size	of	120.
Of	even	more	importance	was	the	effect	of	outlier	exclusion	on	
the	calculated	99th	percentiles.	The	Reed	method	classified	only	
1	subject	as	a	possible	outlier,	 lowering	the	99th	percentile	by	1-	
to	5.9-fold	(method	A)	and	by	1-	to	6.1-fold	(method	B).	However,	
using	 the	TM	method,	1	 to	3	subjects	were	classified	as	possible	
outliers.	 Excluding	 these	 subjects	 from	 the	 calculations	 lowered	
the	99th	percentile	by	1.3-	 to	5.9-fold	 (method	A)	and	by	1.2-	 to	
7.6-fold	(method	B).	The	number	of	outliers	is	presented	in	Table	2.
A	graphical	presentation	of	the	local	derived	cutoff	values	based	
on	120	normal	controls	is	given	in	Figure	2.	The	value	recommended	
by	the	manufacturer	is	indicated	for	comparison.	In	general,	the	95th	
percentile	 cutoffs	were	 lower	 than	 the	manufacturers’	 cutoffs.	 In	
contrast,	 the	99th	percentile	cutoffs	were	equal	 to	or	higher	 than	
the	manufacturers’	cutoffs.
3.3 | Agreement of the 4 assays for aPL testing
HemosIL	AcuStar,	BioPlex,	EliA,	and	QUANTA	Lite	were	compared	
using	573	samples.	Figure	3	shows	the	kappa	statistics	among	the	
HemosIL	AcuStar,	BioPlex,	EliA,	and	QUANTA	Lite	aPL	panels	at	dif-
ferent	cutoffs	defining	positivity.
With	the	manufacturers’	cutoff	(dotted	lines	in	Figure	3),	Cohen's	
kappa	indicated	good	agreement	for	aβ2GPI	IgM	(kappa	coefficient,	
0.69-0.79),	 aβ2GPI	 IgG	 (kappa	 coefficient,	 0.64-0.87)	 and	 aCL	 IgG	
(kappa	coefficient,	0.71-0.86)	with	all	assays.	The	lowest	agreement	
(kappa	coefficient,	0.44-0.65)	was	obtained	for	aCL	IgM,	except	for	
the	comparison	between	HemosIL	AcuStar	and	BioPlex.
F I G U R E  2  Dot	plot	of	aPL	results	from	normal	controls.	(A)	AcuStar	aβ2GPI	IgM	(n	=	120),	(B)	AcuStar	aCL	IgM	(n	=	120),	(C)	AcuStar	
aβ2GPI	IgG	(n	=	120),	(D)	AcuStar	aCL	IgG	(n	=	120),	(E)	BioPlex	aβ2GPI	IgM	(n	=	120),	(F)	BioPlex	aCL	IgM	(n	=	120),	(G)	BioPlex	aβ2GPI	IgG	
(n	=	120),	(H)	BioPlex	aCL	IgG	(n	=	120),	(I)	EliA	aβ2GPI	IgM	(n	=	120),	(J)	EliA	aCL	IgM	(n	=	120),	(K)	EliA	aβ2GPI	IgG	(n	=	120),	(L)	EliA	aCL	IgG	
(n	=	120),	(M)	QUANTA	Lite	aβ2GPI	IgM	(n	=	120),	(N)	QUANTA	Lite	aCL	IgM	(n	=	120),	(O)	QUANTA	Lite	aβ2GPI	IgG	(n	=	120),	(P)	QUANTA	
Lite	aCL	IgG	(n	=	120).	aβ2GPI,	anti-β2	glycoprotein	I	antibodies;	aCL,	anticardiolipin	antibodies;	GPL,	IgG	phospholipid	units;	method	A,	p	
(n	+	1),	where	p	indicates	the	percentile	and	n	indicates	the	sample	size;	method	B,	pn	+	0.5,	where	p	indicates	the	percentile	and	n	indicates	
the	sample	size;	MPL,	IgM	phospholipid	units;	P,	percentile;	SGU,	standard	IgG	units;	SMU,	standard	IgM	units;	TM,	Tietjen-Moore
     |  521VANOVERSCHELDE Et AL.
99th P method A
99th P method A, Reed
99th P method A, TM
99th P method B
99th P method B, Reed
99th P method B, TM
95th P method A
95th P method A, Reed
95th P method A, TM
95th P method B
95th P method B, Reed
95th P method B, TM
Manufacturer’s cutoff
AcuStar aβ2GPI IgM
40 300 200 50
40
30
20
10
0
150
100
50
0
250
200
150
100
50
0
30
20
U
/m
L
U
/m
L
U
/m
L
U
/m
L
U
/m
L
U
/m
L
U
/m
L
U
/m
L
10
0
AcuStar aCL IgM AcuStar aβ2GPI IgG AcuStar aCL IgG
BioPlex aβ2GPI IgM
80
60
140
200
150
100
50
0
120
100
80
60
40
20
0
M
P
L-
U
/m
L
M
P
L-
U
/m
L
G
P
L-
U
/m
L
G
P
L-
U
/m
L
40
20
0
60
40
20
0
BioPlex aCL IgM BioPlex aβ2GPI IgG BioPlex aCL IgG
EliA aβ2GPI IgM
25
20
15
10
5
0
25 40 60
50
40
30
20
10
0
30
20
10
0
20
15
10
5
0
EliA aCL IgM EliA aβ2GPI IgG EliA aCL IgG
QUANTA Lite aβ2GPI IgM
S
M
U
M
P
L
S
G
U
G
P
L
30
25
20
15
10
5
0
30 20 80
60
40
20
0
15
10
5
0
25
20
15
10
5
0
QUANTA Lite aCL IgM QUANTA Lite aβ2GPI IgG QUANTA Lite aCL IgG
(A) (B) (C) (D)
(E) (F) (G) (H)
(I) (J) (K) (L)
(M) (N) (O) (P)
522  |     VANOVERSCHELDE Et AL.
F I G U R E  3  Kappa	agreement	among	aPL	assays	at	manufacturer	and	in-house	cutoff	values.	aβ2GPI,	anti-β2	glycoprotein	I	antibodies;	
aCL,	anticardiolipin	antibodies;	method	A,	p	(n	+	1),	where	p	indicates	the	percentile	and	n	indicates	the	sample	size;	method	B,	pn	+	0.5,	
where	p	indicates	the	percentile	and	n	indicates	the	sample	size;	P,	percentile;	TM,	Tietjen-Moore.	Dotted	lines	represent	kappa	agreement	
at	manufacturers’	cutoff	values
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With	all	99th	percentile	 cutoffs	 investigated	 (based	on	120	
normal	 controls),	 kappa	 ranged	 from	 0.52	 to	 0.90	 for	 aβ2GPI	
IgM;	from	0.22	to	0.73	for	aCL	IgM;	from	0.71	to	0.97	for	aβ2GPI	
IgG;	and	from	0.63	to	0.95	for	aCL	IgG.	With	all	95th	percentile	
cutoffs	 investigated	 (based	 on	 120	 normal	 controls),	 kappa	
ranged	from	0.55	to	0.82	for	aβ2GPI	IgM,	from	0.29	to	0.74	for	
aCL	IgM,	from	0.29	to	0.72	for	aβ2GPI	IgG,	and	from	0.37	to	0.61	
for	aCL	IgG.
F I G U R E  4  Global	odds	ratio,	sensitivity,	specificity,	and	Youden	index	for	prediction	of	thrombotic	events	using	manufacturer	and	in-
house	cutoff	values	(A)	calculated	on	120	normal	controls;	(B)	calculated	on	200	normal	controls.	Method	A,	p	(n	+	1),	where	p	indicates	the	
percentile	and	n	indicates	the	sample	size;	method	B,	pn	+	0.5,	where	p	indicates	the	percentile	and	n	indicates	the	sample	size;	OR,	odds	
ratio;	P,	percentile;	sens,	sensitivity;	spec,	specificity;	TM,	Tietjen-Moore;	YI,	Youden	index
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3.4 | Diagnostic performances
We	compared	the	results	for	aCL	and	aβ2GPI	antibodies	obtained	
with	HemosIL	AcuStar,	 BioPlex,	 EliA,	 and	QUANTA	 Lite	with	 the	
presence	 of	 clinical	 features	 of	 the	 patients.	 Odds	 ratios,	 sensi-
tivities,	 specificities,	 and	Youden	 indexes	 are	 shown	 in	 Tables	 S3	
through	S6.	A	summary	of	these	data	is	shown	in	Figure	4,	show-
ing	 the	 test	 statistics	when	at	 least	1	of	 the	 aPL	panel	 tests	was	
positive.
All	 aCL	 and	 aβ2GPI	 IgM	 assays	 showed	 a	 poor	 relationship	
with	thrombotic	events.	In	contrast,	IgG	positivity	was	found	to	be	
strongly	associated	with	thrombosis.	With	increasing	aPL	titers	(eg,	
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from	the	95th	to	the	99th	percentile),	a	trend	of	an	increased	risk	for	
thrombosis	was	obtained.
With	 the	 manufacturers’	 cutoff,	 the	 sensitivity	 and	 specific-
ity	varied,	respectively,	from	7.1%	to	9.9%	and	94.7%	to	96.3%	for	
aβ2GPI	IgM,	from	8.7%	to	16.3%	and	88.5%	to	96.6%	for	aCL	IgM,	
from	16.3%	to	26.2%	and	96.0%	to	99.4%	for	aβ2GPI	IgG,	and	from	
16.7%	to	22.2%	and	96.9%	to	99.1%	for	aCL	IgG.	This	corresponds	
to	Youden	indexes	varying	from	3.1%	to	5.8%	for	aβ2GPI	IgM,	from	
4.4%	to	5.3%	for	aCL	IgM,	from	15.6%	to	22.1%	for	aβ2GPI	IgG,	and	
from	15.7%	to	19.5%	for	aCL	IgG.
With	all	95th	percentile	cutoffs	investigated	(based	on	120	nor-
mal	 controls),	 the	 sensitivity	 and	 specificity	 varied	 from	 8.7%	 to	
19.4%	and	85.7%	to	95.0%	for	aβ2GPI	IgM,	from	8.3%	to	27.8%	and	
76.9%	 to	 96.3%	 for	 aCL	 IgM,	 from	25.8%	 to	 41.3%	 and	 76.9%	 to	
91.0%	for	aβ2GPI	IgG,	and	from	25.0%	to	36.1%	and	82.2%	to	95.6%	
for	aCL	IgG.	This	corresponds	to	Youden	indexes	varying	from	3.7%	
to	10.7%	for	aβ2GPI	IgM,	from	3.3%	to	8.9%	for	aCL	IgM,	from	12.8%	
to	29.2%	for	aβ2GPI	IgG,	and	from	15.9%	to	23.8%	for	aCL	IgG.
With	 all	 99th	 percentile	 cutoffs	 investigated	 (based	 on	 120	
normal	 controls),	 the	 sensitivity	 and	 specificity	 varied	 from	 4.0%	
to	13.9%	and	91.3%	to	97.8%	for	aβ2GPI	IgM,	from	0.8%	to	15.9%	
and	88.8%	to	99.1%	for	aCL	IgM,	from	14.3%	to	23.0%	and	95.3%	
to	99.7%	 for	 aβ2GPI	 IgG,	 and	 from	10.7%	 to	23.0%	and	95.0%	 to	
100.0%	 for	 aCL	 IgG.	 This	 corresponds	 to	Youden	 indexes	 varying	
from	1.8%	to	5.8%	for	aβ2GPI	IgM,	from	−0.1%	to	6.8%	for	aCL	IgM,	
from	14.0%	to	19.2%	for	aβ2GPI	IgG	and	from	10.7%	to	18.7%	for	
aCL	IgG.	The	highest	Youden	index	was	obtained	when	cutoffs	were	
calculated on outlier deleted data.
4  | DISCUSSION
Defining	cutoff	 reference	values	 for	 aPL-solid	phase	assays	 is	one	
of	 the	 factors	 that	determines	 the	classification	of	a	patient	as	an	
APS	patient	or	not.	The	 interpretation	of	 results	 is	determined	by	
the	cutoff	values	and	plays	a	major	role	in	classifying	a	sample	as	aPL	
positive	or	 negative.	 aCL	 and	 aβ2GPI	 results	 are	 not	 expressed	 in	
International	Units	because	of	the	lack	of	an	international	reference	
standard;	rather,	they	are	expressed	in	arbitrary	units	according	to	
the	calibration	curve	used	in	the	method.	The	test	signal	is	converted	
into	antibody	units	derived	from	the	calibration	curve.	Usually,	these	
assay	results	are	called	semiquantitative	despite	the	use	of	calibra-
tion	 curves,	 and	 results	of	 aCL	and	aβ2GPI	 tests	 are	expressed	 in	
units	on	a	continuous	scale.	Each	test	result	above	the	cutoff	value	
calculated	 as	 higher	 than	 the	 99th	 percentile	 should	 be	 regarded	
as	positive,	according	to	the	SSC	recommendations	for	solid-phase	
assays.6
SSC-aPL	 recommendations	 were	 published	 in	 2014,	 providing	
detailed	information	on	the	execution	of	solid-phase	assays	for	aPL,	
including	 recommendations	 on	 the	 calculation	 of	 cutoff	 values.6 
The	questionnaire	revealed	that	 in	daily	practice,	84.5%	(109/129)	
of	 the	 laboratories	 apply	 cutoff	 values	 according	 to	 the	 recom-
mendations,	either	by	calculating	in-house	cutoffs	(48.6%;	53/109)	
or	 by	 transference	 of	 the	 manufacturer's	 cutoff	 (51.4%;	 56/109).	
Moreover,	 the	 in-house	cutoff	 is	calculated	by	the	99th	percentile	
by	82.4%	of	the	laboratories,	as	advised,	although	not	always	using	
at	least	120	normal	controls	(53.7%);	61.5%	of	the	laboratories	check	
for	outliers	by	various	methods,	and	38.2%	of	those	using	the	manu-
facturer's	cutoff	check	the	cutoffs	before	transferring	them.
The	goal	of	this	study	was	to	calculate	and	compare	cutoff	val-
ues	 for	 aCL	and	aβ2GPI	antibodies	 analyzed	on	4	different	plat-
forms	and	to	define	the	optimal	method	of	calculation	by	analyzing	
the	 diagnostic	 performance	 in	 a	 case-control	 design.	 Previous	
studies	defining	optimal	aPL	cutoffs	focused	on	the	optimal	sep-
aration	of	 cases	and	controls.9,14	However,	 this	approach	has	 in-
herent	weaknesses.15,16	Instead,	we	propose	a	different	approach	
that	 takes	 advantage	 of	 the	 Youden	 index	 to	 select	 the	 optimal	
cutoff	value.
The	 aPL	 results	 from	 the	 normal	 controls	were	 not	 normally	
distributed.	 Therefore,	 cutoff	 values	 were	 determined	 by	 non-
parametric	evaluation	based	on	centiles.	The	cutoffs	obtained	dif-
fered	between	assays	and,	 in	most	of	the	cases,	 from	the	values	
given	by	the	manufacturer.	Moreover,	we	found	an	up	to	11-fold	
difference	 in	 99th	 percentile	 cutoff	 values	 depending	 on	which	
statistical	method	was	used.	Because	the	main	aim	of	our	analysis	
was	to	compare	different	statistical	methods	for	cutoff	establish-
ment,	we	based	our	calculations	on	120	normal	controls.	However,	
different	 values	 were	 obtained	 when	 using	 data	 from	 200	 nor-
mal	 controls,	 pointing	 to	 an	 inherent	degree	of	uncertainty.	The	
recommended	number	of	 1206	 actually	 comes	 from	 the	number	
needed	to	determine	the	90%	CIs	of	the	2.5th	and	97.5th	percen-
tiles	of	a	population	using	nonparametric	statistics.11	 In	fact,	the	
minimum	sample	size	for	a	reliable	estimation	of	the	99th	percen-
tile	is	at	least	300.17
Currently,	only	medium-	or	high-titer	antibodies	are	considered	
clinically relevant.18,19	 This	 study	 confirms	 an	 increased	 risk	 for	
thrombosis	with	increasing	aPL	titers	(eg,	from	the	95th	to	the	99th	
percentile),	although	the	application	of	the	99th	percentile	may	be	
inappropriate	for	clinical	use	due	to	low	sensitivity.	For	example,	for	
HemosIL	AcuStar	aβ2GPI	IgG,	the	titer	of	136.2	U/mL	calculated	as	
the	99th	percentile	of	120	normal	controls	is	associated	with	a	dis-
appointingly	low	sensitivity,	dropping	to	<20%.
When	selecting	subjects	for	a	reference	range	study,	we	assume	
that	the	reference	values	represent	a	“homogeneous”	collection	of	
observations.	The	question	remains	how	to	treat	those	subjects	that	
are	apparently	aberrant.	Many	papers	evaluating	cutoff	values	 for	
aPL	simply	assume	the	absence	of	outliers.20,21	This	is	based	on	the	
assumption	 that	 samples	 from	 normal	 donors	 are	 negative	 for	 all	
aPL.	However,	given	the	high	titer	of	aPL,	the	subjects	classified	as	
outliers	 in	 this	 study	were	 regarded	as	 true	biological	 outliers.	Of	
note,	the	presence	of	aPL	in	a	patient	can	precede	the	occurrence	of	
the	typical	clinical	manifestations.
Our	findings	suggest	the	need	for	outlier	removal	as	a	necessary	
step	before	cutoff	calculation,	as	the	reference	study	is	prone	to	bio-
logical	outliers	on	top	of	analytical	outliers.	The	CLSI	guideline11	sup-
ports	the	use	of	the	Reed	method,	in	which	the	suspected	outlier	is	
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rejected	 if	 the	distance	between	the	value	and	 its	closest	neighbor	
is	more	than	one	third	of	the	range	of	all	values.	However,	this	test	
can	be	used	only	when	1	outlier	is	suspected.22	Tukey's	box	method	
involves	the	labeling	of	extreme	values	by	using	only	the	middle	50%	
of	the	sample,	thus	reducing	the	possible	masking	effect	of	multiple	
outliers	at	1	site	of	the	distribution.	However,	Tukey's	box	method	re-
quires	transformation	to	yield	a	parametric	distribution.	Alternatively,	
a	block	procedure,	such	as	the	TM	test,13,23	is	suggested.	No	further	
details	are	given	in	the	CLSI	document	about	the	use	of	this	method	
that	is	also	not	available	in	conventional	statistical	software	programs.	
The	 existence	 and	 support	 of	 multiple	 outlier	 detection	 methods	
complicates	which	method	should	be	used,	given	the	impact	on	the	
resulting	cutoff	value	and	hence	the	classification	of	patients.
Some	 limitations	of	our	study	should	be	recognized.	First,	 the	
optimal	minimum	number	of	300	normal	donors	was	not	reached.	
This	may	explain	the	considerable	differences	in	cutoff	estimations	
depending	on	the	method	used.	Second,	we	did	not	include	obstetric	
APS	patients	in	this	study.	Some	of	those	patients	may	have	lower,	
yet	persistent,	aPL	levels	and	could	be	more	adversely	affected	by	
cutoff	calculations.	A	small	number	of	reports24‒26	associate	low	ti-
ters	of	aPL	with	an	increased	risk	of	obstetric	complications,	though	
further	confirmation	in	additional	studies	is	necessary.
Considering	the	diagnostic	 importance	of	 the	99th	percentile	
in	 the	 prediction	 of	 APS-related	 thrombosis,	 we	 emphasize	 the	
need	for	standardized	criteria	concerning	the	statistical	analysis	to	
define	the	99th	percentile.	Based	on	our	results,	we	recommend	
the	use	of	a	nonparametric	procedure	based	on	at	least	300	sam-
ples	from	normal	donors.	To	identify	outlier	data,	we	recommend	
the	use	of	the	Reed	method	given	its	simplicity.	Moreover,	applying	
this	outlier	exclusion	method	results	in	a	high	Youden	index.
The	 sample	 size	 requirement	 causes	 a	 problem	 concern-
ing	 the	 feasibility	 of	 local	 laboratories	 to	 establish	 cutoff	 values.	
Verification	 of	 the	 manufacturer's	 cutoff	 using	 a	 small	 number	
may	be	an	alternative	when	local	cutoff	calculation	is	not	feasible.6 
However,	this	would	assume	that	manufacturers’	cutoffs	are	estab-
lished	 by	 appropriate	 statistical	models	 using	 a	 sufficiently	 large	
donor	 population.	 In	 our	 experience,	 this	 is	 not	 always	 the	 case.	
A	better	alternative	to	establish	cutoff	values	is	a	multicenter	ap-
proach.	Previously,	it	was	demonstrated	that	a	multicenter	approach	
can	determine	the	cutoff	values	with	a	higher	accuracy	by	increas-
ing	the	number	of	healthy	blood	bank	donors.21	An	interlaboratory	
cutoff	 value	 established	 by	 users	 of	 an	 identical	 automated	 sys-
tem,	applying	the	same	sample	type	with	comparable	demographic	
characteristics	of	patients,	was	evaluated	as	a	valuable	alternative	
by	90%	of	the	participants	of	the	questionnaire.	Joint	efforts	of	in-
dependent	organizations,	such	as	national	or	international	external	
quality	 control	 organizations	or	 standardization	 committees	 such	
as	the	SSC-aPL,	can	render	this	approach	more	cost-effective	and	
achievable,	having	the	advantage	of	pooling	results	of	higher	num-
bers	of	normal	donors,	and	applying	a	good	design.
Uniformity	in	the	calculation	of	cutoff	values	will	lead	to	an	im-
proved	and	more	standardized	interpretation	of	assays	and	benefit	
the	complex	diagnosis	of	APS.
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